These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16860461)

  • 61. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chemotherapy in hormone refractory prostate cancer: where do we stand?
    Clarke NW; Wylie JP
    Eur Urol; 2004 Dec; 46(6):709-11. PubMed ID: 15548436
    [No Abstract]   [Full Text] [Related]  

  • 64. The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.
    Mackler MA; Liberti JP; Smith MJ; Koontz WW; Prout GR
    Invest Urol; 1972 Mar; 9(5):423-5. PubMed ID: 5016026
    [No Abstract]   [Full Text] [Related]  

  • 65. Eligard. Tiny implant fights prostate cancer.
    Nursing; 2002 May; 32(5):18. PubMed ID: 12035639
    [No Abstract]   [Full Text] [Related]  

  • 66. The moving landscape of locally advanced prostate cancer: combination of external irradiation and endocrine treatment and/or multimodal approach.
    Bolla M
    Eur Urol; 2012 Aug; 62(2):220-1; author reply 222-3. PubMed ID: 22552217
    [No Abstract]   [Full Text] [Related]  

  • 67. Male breast cancer during treatment with leuprolide for prostate cancer.
    Yacoub J; Richardson C; Farmer M; Lee WR; Clark PE; Hurt G; Levine EA
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):555-6; discussion 556-7. PubMed ID: 17679929
    [No Abstract]   [Full Text] [Related]  

  • 68. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
    Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
    [No Abstract]   [Full Text] [Related]  

  • 72. Re: Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
    Vikram B
    J Natl Cancer Inst; 2006 Dec; 98(24):1826; author reply 1826. PubMed ID: 17179485
    [No Abstract]   [Full Text] [Related]  

  • 73. Nonalcoholic fatty liver disease induced by leuprorelin acetate.
    Gabbi C; Carubbi F; Losi L; Loria P; Costantini M; Bertolotti M; Carulli N
    J Clin Gastroenterol; 2008 Jan; 42(1):107-10. PubMed ID: 18097299
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.
    Weight CJ; Klein EA; Jones JS
    Cancer; 2008 May; 112(10):2195-201. PubMed ID: 18393326
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    Vis AN; Schröder FH
    BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Current status and prospects of androgen depletion therapy for prostate cancer.
    Akaza H
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Adapting treatment for prostate cancer according to risk of disease progression.
    Anderson J; Sternberg CN
    Crit Rev Oncol Hematol; 2008 Oct; 68 Suppl 1():S23-31. PubMed ID: 18752970
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Re: Prostate cancer: a brief history and the discovery of hormonal ablation treatment.
    Schultheiss D; Machtens S
    J Urol; 2002 Apr; 167(4):1801. PubMed ID: 11912427
    [No Abstract]   [Full Text] [Related]  

  • 80. The association between measures of progression and survival in castrate-metastatic prostate cancer.
    Scher HI; Warren M; Heller G
    Clin Cancer Res; 2007 Mar; 13(5):1488-92. PubMed ID: 17332293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.